Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Fat; Liver Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects

NCT02974374
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
PF-06835919, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis

NCT01703260
View directory record Official record
Conditions
Nonalcoholic Steatohapatitis
Interventions
Roflumilast, Pioglitazone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Coronado, California • Annapolis, Maryland • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

NCT02287779
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT03248882
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Placebo, PF-05221304
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
60
States / cities
Bakersfield, California • Chula Vista, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 1 Interventional

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

NCT00706537
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis(NASH)
Interventions
Active treatment, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Anaheim, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Not applicable Interventional Results available

Mild Hypothermia and Acute Kidney Injury in Liver Transplantation

NCT03534141
View directory record Official record
Conditions
Cirrhosis, End Stage Liver Disease, Acute Kidney Injury, Liver Transplant; Complications, Chronic Kidney Diseases, Hepatitis c, Hepatitis B, NASH - Nonalcoholic Steatohepatitis, Alcoholic Cirrhosis, Hepatocellular Carcinoma
Interventions
Esophageal cooling/warming device, Mild hypothermia, Normothermia
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 29, 2026, 1:35 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Not applicable Interventional Results available

Endoscopic Ultrasound(EUS)-Guided TRUCUT Biopsy (EUS-TCB) of Suspected Nonalcoholic Fatty Liver Disease(NAFLD.)

NCT00586313
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Tru-cut biopsy, Tru-cut
Device · Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Phase 4 Interventional Results available

Pioglitazone to Treat Fatty Liver in Patients With HIV and Hepatitis C Infections

NCT00742326
View directory record Official record
Conditions
HIV, Hepatitis C, Liver Disease, Fatty Liver, Steatosis
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CS0159 in Subjects With NASH

NCT05591079
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
CS0159 (Linafexor)
Drug
Lead sponsor
Cascade Pharmaceuticals, Inc
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
17
States / cities
Gardena, California • Huntington Park, California • Panorama City, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 3 Interventional

S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis

NCT00108589
View directory record Official record
Conditions
Hepatitis
Interventions
S-adenosylmethionine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

NCT04048876
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
Interventions
CC-90001, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.

NCT02196051
View directory record Official record
Conditions
Insulin Resistance
Interventions
one bout of 45 minutes exercise
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 29, 2026, 1:35 PM EDT
Recruiting Phase 2 Interventional

Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

NCT06133101
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Standard Soy Milk, 2% Fat Cow's Milk
Drug
Lead sponsor
Marialena Mouzaki
Other
Eligibility
5 Years to 16 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Tirzepatide, Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
142
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity

NCT06335771
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver, Diabetes Type 2, Healthy
Interventions
Dietary consultation weight loss intervention
Other
Lead sponsor
Bettina Mittendorfer
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effect of Weight Loss and Exercise on Liver and Muscle Fat in Obese Elderly

NCT00779207
View directory record Official record
Conditions
Obesity
Interventions
weight loss and exercise, weight loss
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.

NCT04065841
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Tropifexor, Licogliflozin, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Coronado, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Not applicable Interventional

Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)

NCT05423327
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
No Intervention
Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
5,311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
30
States / cities
Coronado, California • Gardena, California • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Sep 29, 2026, 1:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Sep 29, 2026, 1:35 PM EDT
Terminated Not applicable Interventional Results available

Ultrasound Method to Measure Fibrosis of the Liver in Children

NCT02086708
View directory record Official record
Conditions
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV, Drug-Induced Liver Injury
Interventions
Shear Wave sonoelastography
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 29, 2026, 1:35 PM EDT